Perrigo Company plc

PRGO Healthcare Drug Manufacturers Specialty & Generic

Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 3.17%, EPS grew 1,000.0%, free cash flow grew 18.4% and total debt fell 9.78%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.

16.63 0.15 +0.91%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−77.4×
Dividend yield
6.98%
F-score
4/9
Altman Z
−0.08
Beneish M
−3.51
Dividend safety
16/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 4 5

+8 more TTM periods

ROE
(49.65%) (52.97%) (39.29%) (1.15%)
ROA
(19.60%) (20.49%) (15.68%) (0.49%)
ROIC
(18.06%) (16.68%) (11.60%) 2.28%
Return on Tangible Assets
(77.24%) (70.11%) (53.12%) (1.96%)
Average Days of Receivables
62.51 60.89 52.59 54.93
Free Cash Flow per Share
0.86 0.83 1.11 2.05
Free Cash Flow
119.30 115.70 153.40 283.60
Other line items

Show all line items

Columns are period end dates